EZH2 and neoplasm: In previous research, EZH2 catalyzed the mono-, di-, and tri-methylation of histone H3K27, silencing various genes [42], including the tumor suppressor genes, thus facilitating the progression of cancer cells in various malignancies, including the breast [43] and gastric [44] cancers, and conferring resistance to CDDP chemotherapy [45, 46].